Valuation dashboard for Keros Therapeutics, Inc. (KROS) with P/E N/A, P/B 0.81, EV/EBITDA -1.38 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options.
Analysis Summary
Trailing-twelve-month margins: gross margin 94.7%, operating margin -6.8%, net margin -5.5%.
At the current price of $10.74, KROS has negative trailing earnings (P/E not meaningful) and an ROE of -21.40%. Market capitalisation stands at $344M.
Balance sheet quality for KROS: current ratio of 15.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.81 |
| EV / EBITDA | -1.38 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | $344M | 0.81 | -21.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $10.74 |
| Market Cap | $344M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -21.40% |
| Return on Invested Capital | -35.25% |
| Return on Assets | -28.91% |
| Gross Margin | 94.68% |
| Operating Margin | -675.82% |
| Net Margin | -553.88% |
Related companies: ABSI · CRVS · CTMX · MLTX · NAGE · OLMA · RGNX
Explore sector: Healthcare · Biotechnology
More sections of KROS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks